Pdx Pharmaceuticals
PDX Pharmaceuticals is a biopharmaceutical company focused on developing next-generation cancer immunotherapies using nanotechnology and cancer systems biology. Their mission is to substantially improve healthcare through innovative nanotechnology platforms that enable targeted delivery of therapeutics, vaccines, and immunotherapies. They aim to build significant value in their nanomaterial drug candidates that address unmet medical needs, with a strategic focus on creating therapies that overcome resistance and trigger cancer-specific immune responses.
Industries
Nr. of Employees
small (1-50)
Patents
Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor
US-12059500-B2
View DetailsTherapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor
US-11679082-B2
View DetailsTherapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor
US-11224573-B2
View Details
Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor
US-12059500-B2
View DetailsTherapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor
US-11679082-B2
View DetailsTherapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor
US-11224573-B2
View DetailsProducts
Systemic nanoparticle immunotherapy candidate (co-delivering kinase inhibitor and immune checkpoint agent)
A systemically administered nanoparticle formulation designed to co-deliver a kinase-targeting agent and an immune checkpoint–targeting modality to tumors to combine cytotoxic and immune-modulatory mechanisms.
Intratumoral nanoparticle vaccine platform (co-delivering gene-silencing agent and adjuvant)
Locally administered nanoparticle formulation that co-delivers gene-silencing payloads and immune adjuvants to treated tumors to generate systemic antitumor adaptive immune responses without individualized neoantigen identification.
HER2-targeted nanoparticle delivering gene-silencing agent and chemotherapeutic
A targeted nanoparticle designed for HER2-positive breast cancer that co-loads a gene-silencing payload against HER2 with a chemotherapeutic agent and a targeting component to increase selectivity.
Nanoparticle co-delivering cell-cycle inhibitor and receptor-targeting agent as a radiation sensitizer
A formulation combining a cell-cycle/repair-targeting payload with a receptor-targeting component to reduce DNA repair and cell-cycle progression in tumor cells, thereby enhancing radiotherapy response in preclinical studies.
Nanoparticle-based antigen vaccine candidate (preclinical)
A nanoparticle vaccine formulation that delivers antigen together with immune-modulating components to enhance antibody and cellular responses in preclinical immunogenicity studies.
Systemic nanoparticle immunotherapy candidate (co-delivering kinase inhibitor and immune checkpoint agent)
A systemically administered nanoparticle formulation designed to co-deliver a kinase-targeting agent and an immune checkpoint–targeting modality to tumors to combine cytotoxic and immune-modulatory mechanisms.
Intratumoral nanoparticle vaccine platform (co-delivering gene-silencing agent and adjuvant)
Locally administered nanoparticle formulation that co-delivers gene-silencing payloads and immune adjuvants to treated tumors to generate systemic antitumor adaptive immune responses without individualized neoantigen identification.
HER2-targeted nanoparticle delivering gene-silencing agent and chemotherapeutic
A targeted nanoparticle designed for HER2-positive breast cancer that co-loads a gene-silencing payload against HER2 with a chemotherapeutic agent and a targeting component to increase selectivity.
Nanoparticle co-delivering cell-cycle inhibitor and receptor-targeting agent as a radiation sensitizer
A formulation combining a cell-cycle/repair-targeting payload with a receptor-targeting component to reduce DNA repair and cell-cycle progression in tumor cells, thereby enhancing radiotherapy response in preclinical studies.
Nanoparticle-based antigen vaccine candidate (preclinical)
A nanoparticle vaccine formulation that delivers antigen together with immune-modulating components to enhance antibody and cellular responses in preclinical immunogenicity studies.
Services
Synthesis, optimization, and physicochemical characterization of nanoparticle formulations for co-delivery of nucleic acids, small molecules, and immunomodulators.
Design and execution of rodent tumor models to evaluate antitumor efficacy, immune cell dependency, memory responses, and combinational treatment effects with checkpoint inhibitors or radiotherapy.
Execution of studies and coordination required for IND-enabling packages, and interactions with regulatory bodies to advance candidates toward clinical trials.
Partnered engagements with national characterization laboratories for comprehensive particle characterization and standardized assay support.
Synthesis, optimization, and physicochemical characterization of nanoparticle formulations for co-delivery of nucleic acids, small molecules, and immunomodulators.
Design and execution of rodent tumor models to evaluate antitumor efficacy, immune cell dependency, memory responses, and combinational treatment effects with checkpoint inhibitors or radiotherapy.
Execution of studies and coordination required for IND-enabling packages, and interactions with regulatory bodies to advance candidates toward clinical trials.
Partnered engagements with national characterization laboratories for comprehensive particle characterization and standardized assay support.
Expertise Areas
- Nanoparticle drug delivery
- Co-delivery of nucleic acids and small molecules
- Cancer immunotherapy and in situ tumor vaccination
- siRNA therapeutic development
Key Technologies
- Mesoporous silica nanoparticle platforms
- Polymer-coated and bioreducible-crosslinked polymer coatings
- Co-loading and co-delivery of nucleic acids and small molecules
- Antibody- and ligand-conjugated targeting
News & Updates
Dr. Wassana Yantasee, CEO of PDX Pharmaceuticals, was inducted into the National Academy of Inventors for her contributions to cancer therapeutics.
Dr. Wassana Yantasee was selected as a semi-finalist in the AIM-HI Women’s Venture Competition in Oncology, highlighting her innovative nano-platform for cancer immunotherapies.
PDX Pharma received a Notice of Allowance for a U.S. patent covering their core nanoparticle platform, Pdx-NP, which is used for targeted delivery of therapeutics.
Dr. Wassana Yantasee, CEO of PDX Pharmaceuticals, was inducted into the National Academy of Inventors for her contributions to cancer therapeutics.
Dr. Wassana Yantasee was selected as a semi-finalist in the AIM-HI Women’s Venture Competition in Oncology, highlighting her innovative nano-platform for cancer immunotherapies.
PDX Pharma received a Notice of Allowance for a U.S. patent covering their core nanoparticle platform, Pdx-NP, which is used for targeted delivery of therapeutics.